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Objectives: We aimed to (1) study factors that determine the use of invasive procedures in the man-
agement of acute myocardial infarction (AMI) in patients with dementia and (2) determine whether the
use of invasive procedures was associated with their better survival.
Design: Cohort study based on patients registered in the Swedish Dementia Registry (SveDem), 2007e2012.
Median follow-up time was 228 days.
Setting: Patients diagnosed with dementia in specialist memory clinics and primary care units in Sweden.
Participants: A total of 525 patients with dementia who suffered AMI (mean age 89 years, 54% women).
Measurements: Information on AMI and use of invasive procedures (coronary angiography and percu-
taneous coronary intervention) was obtained from Swedish national health registers. Binary logistic
regression was applied to study associations of patients’ characteristics with the use of invasive pro-
cedures; odds ratios (ORs) with 95% conﬁdence intervals (CIs) were calculated. Survival was analyzed
with Kaplan-Meier curves; log-rank test was used to compare survival of patients who received an
invasive procedure versus those who did not receive it. Cox regressionwas applied to study association of
the invasive procedures with all-cause mortality; hazard ratios (HRs) with 95% CIs were calculated.
Results: One hundred ten patients (21%) with dementia received an invasive procedure in the manage-
ment of AMI. After multivariate adjustment, lower age and higher global cognitive status were associated
with the use of invasive procedures. The invasively managed patients survived longer (P ¼ .001). The use
of invasive procedures was associated with a lower risk of all-cause mortality, adjusting for type of AMI
and dementia disorder, age, gender, registration unit, history of AMI and comorbidity score (HR 0.35, 95%
CI 0.21e0.59), or total number of drugs (HR 0.34, 95% CI 0.20e0.58).
Conclusion: Age and cognitive status determine the use of invasive procedures in patients with dementia.
This study suggests that the invasive management of AMI has a beneﬁt for survival of patients with
dementia.
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P. Cermakova et al. / JAMDA 18 (2017) 19e2320Acute myocardial infarction (AMI) is one of the leading causes of
death and is particularly prevalent and deadly after 80 years of age.1,2
Based on electrocardiographic ﬁndings, AMI can present as myocardial
infarction with ST-elevation (STEMI) or myocardial infarction without
ST-elevation (NSTEMI).1,3 NSTEMI is themost commonmanifestation of
AMI in older people, accounting for 75% of AMI cases among patients
80 years and older.4,5 Compared to younger individuals, the manage-
mentofAMI inelderlypatientshas been traditionallymore conservative,
mostly because of their comorbidities, higher risk of complications of
invasive procedures, cognitive decline, atypical symptoms leading to
delayed hospital admission and higher risk of death.6,7 Consequently,
this can lead to limited access to optimal treatment.
The use of invasive procedures such as coronary angiography and
revascularization with percutaneous coronary intervention (PCI) has
signiﬁcantly contributed to improved survival of patients, especially
among younger individuals and men.1,3,4 Present guidelines recom-
mend an early invasive strategy for STEMI patients and assessment for
the invasive management in patients with NSTEMI.1,3 However, cor-
onary angiography and PCI are still not used in all individuals who
could beneﬁt from this treatment, possibly because of advanced age,
comorbidities, cognitive impairment, or gender.1,3,8e11
Dementia is an age-related syndrome characterized by progressive
cognitive impairment and is associated with lower utilization of cor-
onary angiography and PCI in patients with AMI.10e13 Because of lack
of evidence from randomized clinical trials, reduced life expectancy,
and risk of adverse side effects, clinicians face difﬁcult decisions
regarding treating AMI in patients with dementia. We aimed to study
factors that inﬂuence the use of invasive procedures (coronary angi-
ography and PCI) in themanagement of AMI in patientswith dementia
and investigate whether the invasive strategy was associated with
better survival. Because several studies have suggested that fewer
women with AMI are managed invasively,8,9 we additionally studied
associations of gender with the use of the invasive procedures.Methods
We performed a cohort study of patients diagnosed with dementia
and registered in the Swedish Dementia Registry (SveDem). Data on
other diagnoses than dementia, procedures, and drugs were obtained
from the Swedish National Patient Register and the Swedish Prescribed
DrugRegister.Dataondeath camefromtheSwedishPopulationRegister.
We studied 29,630 patients who were registered in SveDem be-
tweenMay1, 2007, andDecember 31, 2012. Between the registration to
SveDem and the end of follow-up (at death or in December 31, 2012;
median 781 days, interquartile range 770 days), 525 patients had a
record of AMI as themain diagnosis (ﬂowchart presentedon Figure S1).
This study complies with the Declaration of Helsinki and was
approved by the regional ethical review board in Stockholm, Sweden.
Patients were informed of the entry to SveDem and had a possibility to
decline participation. Data were deidentiﬁed before analysis.Source of Data
SveDem (www.svedem.se) is a national register that was estab-
lished onMay 1, 2007, with the aim to improve the quality of dementia
care in Sweden and was previously described in detail.14 Brieﬂy, pa-
tients are registered by physicians in memory clinics or primary care
units at the time of the dementia diagnosis with information about
their global cognitive status measured by Mini Mental State Exami-
nation (MMSE). In the present study we assigned patients to four
groups by the type of dementia disorder: Alzheimer disease (including
early and late onset), mixed dementia, vascular dementia and “other
dementias” (including dementia with Lewy bodies, Parkinson disease
dementia, frontotemporal dementia and unspeciﬁed dementia).The Swedish National Patient Register covers inpatient and
outpatient care encounters in Sweden.15 The diagnoses are coded
according to the International Classiﬁcation of Diseases 10 (ICD 10)
and registered at discharge as 1main diagnosis and up to 21 additional
diagnoses. Moreover, the register includes codes for interventional
procedures.
The Swedish Prescribed Drug Register contains information on
prescribed drugs, coded according to the Anatomical and Ther-
apeutical Classiﬁcation (ATC), which were dispensed at Swedish
pharmacies to the entire Swedish population.16
Diagnosis of AMI and Invasive Management
Data on incident cases of AMI were extracted from the Swedish
National Patient Register, if the ICD 10 code of AMI was present as the
main diagnosis after the registration to SveDem and before December
31, 2012. We did not use AMI codes presented as additional diagnoses
to eliminate the risk of including old cases of AMI. We restricted the
analyses to the ﬁrst cases of AMI after the dementia diagnosis. STEMI
was deﬁned by codes I21.0eI21.3, NSTEMI by I21.4, and unspeciﬁed
AMI by I21.9. Invasive management was deﬁned as use of coronary
angiography (code AF037) or PCI (codes FNG02 and FNG05), occurring
during the hospitalization for AMI. History of AMI was deﬁned by
codes I21.0eI21.9, if present at any position in the register at least once
between January 1, 2000, and the date of the studied AMI.
Comorbidity and Drugs
We used 9 comorbidities, as suggested for patients with AMI by So
and colleagues.17 We deﬁned them by an ICD 10 code, if present in the
Swedish National Patient Register at any position (as main diagnosis
or additional diagnoses) at least once between January 1, 2000, and
the date of the studied AMI. In addition, we assigned 1 point for each
disease and used the sum as a comorbidity scorewith a maximum of 9
points. The ICD 10 codes are presented in Table S1a.
Information on drugs that were dispensed between July 1, 2005,
and August 31, 2013, was extracted from the Swedish Prescribed Drug
Register. As in our previous study,18 the prescription was identiﬁed at
7 time points; at the date of registration to SveDem and in 1-year
intervals 3 years before and after it. In the present study, we coun-
ted the prescription if the ATC code was found at least once from up to
3 years before the registration to SveDem until the date of the studied
AMI. Moreover, we used total number of drugs at the time of regis-
tration to SveDem as a proxy for overall comorbidity.19 The ATC codes
are presented in Table S1b.
Statistical Analysis
We present descriptive data as means  standard deviation (SD),
median [interquartile range (IQR)] or frequency (n, %), where appro-
priate. To compare characteristics between groups (STEMI vs NSTEMI
vs unspeciﬁed AMI; women vs men; invasive management vs no
invasive management), we applied an independent sample t test or
1-way analysis of variance (ANOVA) for continuous variables with
normal distribution, Mann-Whitney U test, or Kruskal-Wallis test for
continuous variables with skewed distribution and chi-square test or
Fisher exact test for categorical variables.
To study which factors determine the invasive management of AMI
(use of coronary angiography or PCI), we applied binary logistic regres-
sion to estimate odds ratios (ORs)with 95% conﬁdence intervals (CIs) for
associations of patients’ characteristics with the invasive management.
As described above, we used two measures of overall comorbidity (co-
morbidity score and total number of drugs) and present two models: In
model 1, we entered type of AMI, age, gender, MMSE score, history of
AMI, registration unit, type of dementia disorder, and comorbidity score.
Table 1
Characteristics of the Study Population (n ¼ 525)
Characteristic Value
Age at AMI, mean  SD 82.4  6.5
Female gender, n (%) 283 (53.9)
Type of AMI, n (%)
STEMI 86 (16.4)
NSTEMI 235 (44.8)
Unspeciﬁed 204 (38.9)
Invasive management, n (%) 110 (21.0)
Coronary angiography 108 (20.6)
PCI 84 (16.0)
History of AMI, n (%) 86 (16.4)
MMSE score at dementia diagnosis, mean  SD 22  5
Registered at memory clinic, n (%) 384 (73.1)
Living in own home, n (%) 487 (92.8)
Dementia disorder, n (%)
Alzheimer disease 152 (29.0)
Mixed dementia 112 (21.3)
Vascular dementia 126 (24.0)
Other dementias 135 (25.7)
Comorbidity,* n (%)
Shock 7 (1.3)
Diabetes mellitus 132 (25.1)
Heart failure 179 (34.1)
Cancer 117 (22.3)
Cerebrovascular disease 137 (26.1)
Pulmonary edema 8 (1.5)
Acute renal disease 20 (3.8)
Chronic renal disease 38 (7.2)
Cardiac dysrhythmia 187 (35.6)
Comorbidity score, median (IQR) 1 (1)
Comorbidity score 3 109 (20.8)
Drugs,y n (%)
RAAS antagonists 258 (49.1)
Beta blockers 292 (55.6)
Vasodilators 164 (31.2)
Diuretics 229 (43.6)
Calcium channel blockers 182 (34.7)
Lipid-lowering drugs 224 (42.7)
Antidiabetic 113 (21.5)
Antithrombotic 385 (73.3)
Cholinesterase inhibitors 192 (36.6)
Memantine 81 (15.4)
Antidepressants 233 (44.4)
Antipsychotic 73 (13.9)
Hypnotics and sedatives 201 (38.3)
Anxiolytics 137 (26.1)
Total number of drugs, median (IQR) 6 (5)
*Comorbidities were deﬁned if present between January 1, 2000, and the date of
the studied AMI.
yDrugs were identiﬁed from up to 3 years before registration to the Swedish
Dementia Registry (SveDem) until the date of AMI. Total number of drugs was
measured at the time of registration to SveDem.
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score was replaced by the total number of drugs. Moreover, to study
factors that determine the invasivemanagement speciﬁcally for patients
with STEMI, NSTEMI, and unspeciﬁed AMI, we repeated the analyses,
while stratiﬁed by type of AMI.
To study whether women with AMI are less likely to be managed
invasively than men, we applied binary logistic regression to estimate
OR with 95% CI for the association of gender with the invasive man-
agement. First, we controlled separately for each characteristic (age,
type of AMI, MMSE score, history of AMI, type of dementia disorder,
registration unit, comorbidity score, and total number of drugs).
Second, we controlled simultaneously for age, type of AMI and MMSE
scores. Third, we added one comorbidity measure (comorbidity score
or total number of drugs) into the model. Fourth, we ran two fully
adjusted models: model 1 was adjusted for type of AMI, age, MMSE
score, history of AMI, type of dementia disorder, registration unit, and
comorbidity score; model 2 had the same variables except that the
comorbidity score was replaced by the total number of drugs.
We assessed survival using Kaplan-Meier curves and used log-rank
test to compare survival of patients who were managed invasively
versus those who were not. We applied Cox regression models to
estimate the hazard ratios (HRs) with 95% CIs for the association of the
invasive management with all-cause mortality, controlling for type of
AMI, age, gender, MMSE score, dementia disorder, registration unit,
history of AMI, comorbidity score (model 1), or total number of drugs
(model 2). The patients were followed from the time of AMI until
death or until the end of follow-up in December 31, 2012, whichever
came ﬁrst. Two-tailed P values of less than .05 were considered to
show statistical signiﬁcance. Data were analyzed using SPSS, version
22 (IBM Corp, Armonk, NY).
Results
Characteristics of the Patients
The study includes 525 patients with dementia (54% women) who
were diagnosed with AMI at the mean age of 82 years (Table 1). Of
those, 110 patients (21%) were managed invasively; coronary angiog-
raphy was used in 108 and PCI in 84 cases. The diagnosis of STEMI was
made in 86 patients, NSTEMI in 235, and unspeciﬁed AMI in 204
patients. History of AMI was found in 16% of the patients.
At the time of registration to SveDem, the patients had a mean
MMSE score of 22. Themajority of the patients (93%) lived in their own
homes. Alzheimer disease was diagnosed in 29% of patients, mixed
dementia in 21%, vascular dementia in 24%, and “other dementias” in
26%. Before hospitalization for AMI, the most common comorbidity
was cardiac dysrhythmia (36%), heart failure (34%), and cerebrovas-
cular disease (26%), and the most frequently prescribed drugs were
antithrombotic drugs (73%), beta blockers (56%), and renin-
angiotensin-aldosterone system (RAAS) antagonists (49%). Overall,
the median value of comorbidity score was 1 (IQR 1); 21% of the study
population had more than 3 comorbidities. At the time of registration
to SveDem, the patients were prescribed a median of 6 (IQR 5) drugs.
Univariate Analysis
The frequency of the invasive management was highest in STEMI
patients (55% vs 18% in NSTEMI vs 10% in unspeciﬁed AMI; P < .001;
Table S2). Patients with STEMI were the youngest (80 years old vs
82 years in NSTEMI vs 83.5 years in unspeciﬁed AMI; P ¼ .001). The
mean MMSE score did not signiﬁcantly differ by the type of AMI.
STEMI patients had the lowest frequency of previous AMI and heart
failure and the lowest use of several drugs, such as beta blockers,
vasodilators, and lipid-modifying, antithrombotic, and antipsychotic
drugs. The highest comorbidity score was found in patients withunspeciﬁed AMI, but the distribution of total number of drugs did not
signiﬁcantly differ by the type of AMI.
Women were less often managed invasively (16% of women vs 27%
of men; P ¼ .002; Table S2) and were older than men (83 years vs
81 years; P< .001; Table S3). The difference in the distribution ofMMSE
score and history of AMI did not signiﬁcantly differ by gender. Women
had a lower frequency of several comorbidities, such as cancer, cere-
brovascular diseases, and chronic renal disease. They had been treated
to a higher extent with diuretics, antidepressants, hypnotics, and sed-
atives and to a lower extent with RAAS antagonists and lipid-modifying
drugs. Women had a lower comorbidity score than men, but the dis-
tribution of total number of drugs did not differ by gender.
Patients who were managed invasively were younger (78 vs
83 years; P < .001; Table S4), less frequently women (41% vs 57%;
P¼ .002), and had a higher MMSE score (24 vs 21; P< .001), compared
to patients who did not receive any invasive procedure. Moreover,
they had a lower frequency of previous AMI, heart failure, cancer, and
chronic renal disease and had been prescribed less diuretics and
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signiﬁcantly differ in the total number of drugs.Fig. 1. Kaplan-Meier survival curve.Multivariate Analysis
Lower age was signiﬁcantly associated with the invasive manage-
ment, after controlling for type of AMI, gender, MMSE score, history of
AMI, registration unit, type of dementia disorder, and comorbidity
score or total number of drugs (OR 0.89, 95% CI 0.85e0.93; Table 2;
model 1 and model 2). Furthermore, a higher MMSE score was asso-
ciated with invasive management, after adjustment for type of AMI,
gender, age, history of AMI, registration unit, type of dementia disor-
der, and comorbidity score (OR 1.19, 95% CI 1.11e1.28; model 1) or total
number of drugs (OR 1.20, 95% CI 1.12e1.29; model 2).
When stratiﬁed by the type of AMI, we found that only higher
MMSE score was associated with the invasive management in STEMI
patients (Table S5, model 1 andmodel 2). In patients with NSTEMI and
unspeciﬁed AMI, a higher MMSE score as well as lower age was
associated with the invasive management in both models. Moreover,
total number of drugs was associated with being managed invasively
in patients with unspeciﬁed AMI (Table S5, model 2).
Women had lower odds of beingmanaged invasively in unadjusted
analysis (OR 0.52, 95% CI 0.34e0.79; Table S6). This association slightly
attenuated, but remained statistically signiﬁcant, after controlling
separately for type of AMI, age, and MMSE score. However, this
became statistically nonsigniﬁcant, when type of AMI, age, and MMSE
scores were entered into the model simultaneously (OR 0.68, 95% CI
0.41e1.14). In the fully adjusted models, female gender was not
associated with the invasive management (model 1: OR 0.63, 95% CI
0.37e1.06; model 2: OR 0.69, 95% CI 0.41e1.16).Survival After AMI
During the median follow-up time of 228 days (IQR 578), 224 pa-
tients (43%) patients died. Among patients who were managed inva-
sively, 89% survived 1 year, whereas only 54% survived 1 year among
patients who did not receive invasive management. The invasively
managed patients survived longer (log-rank test, P¼ .001; Figure 1). In
unadjusted analysis, the invasive management was associated with a
lower risk of all-cause mortality (HR 0.30, 95% CI 0.19e0.47; Table 3).
The association remained statistically signiﬁcant after controlling for
type of AMI, age, gender, type of dementia disorder, registration unit,
history of AMI, and comorbidity (model 1: HR 0.35, 95% CI 0.21e0.59;
model 2: HR 0.34, 95% CI 0.20e0.58).Table 2
Associations of Patients’ Characteristics With Invasive Management (n ¼ 525)
OR (95% CI)
Unadjusted Model 1* Model 2y
Age 0.89 (0.86e0.92)z 0.89 (0.85e0.93)z 0.89 (0.85e0.93)z
Female gender 0.52 (0.34e0.79)x 0.63 (0.37e1.06) 0.69 (0.41e1.16)
MMSE score 1.18 (1.11e1.26)z 1.19 (1.11e1.28)z 1.20 (1.12e1.29)z
History of AMI 0.45 (0.22e0.90)x 1.00 (0.45e2.25) 0.94 (0.42e2.11)
Comorbidity score 0.72 (0.60e087)x 0.80 (0.62e1.02)
Total number of
drugs
0.96 (0.91e1.01) 0.97 (0.91e1.04)
zP < .001; xP < .05.
*Model 1: type of AMI, age, gender, MMSE score, history of AMI, registration unit,
type of dementia disorder, comorbidity score.
yModel 2: type of AMI, age, gender, MMSE score, history of AMI, registration unit,
type of dementia disorder, total number of drugs.Discussion
In this register-based cohort study of patients with dementia, we
found that 21% of them received an invasive procedure (coronary
angiography or PCI) for the management of AMI. This was most
commonly performed in patients with STEMI (55%), less in NSTEMI
(18%), and least in those with unspeciﬁed AMI (10%). An invasive
treatment strategy was associated with lower age and higher global
cognitive status, and also with a subsequent lower risk of death.
This study has several limitations. In line with previous re-
ports,20,21 the number of individuals with dementia hospitalized for
AMI is low. Several cases of AMI may have been unrecognized, likely
because of patients’ inability to verbalize symptoms, atypical pre-
sentation of AMI, and a high proportion of silent myocardial infarc-
tion.22,23 Moreover, patients who died fromAMI out of hospital are not
captured; it is estimated that 20%e40% of patients with AMI die before
they could be hospitalized.24 As we use administrative data, unrec-
ognized misclassiﬁcation in the diagnosis of AMI is possible. On the
other hand, this study has several strengths. We use two measures of
comorbidity that were identiﬁed from Swedish health registers, which
have almost a complete national coverage. In addition, loss of follow-
up is unlikely, as the outcome (all-cause mortality) was identiﬁed
through a nationwide register.
We found that invasive management was the most frequent in
STEMI patients (55%), reﬂecting the guidelines recommending an
early invasive strategy for those patients.3 Eighteen percent of NSTEMI
patients were managed invasively in our study. Studies performed in
the population of octogenarians report that approximately 80% of
STEMI and 20%e30% of NSTEMI patients are managed invasively.25e29
On the other hand, invasive management was used only in 10% of
patients with unspeciﬁed AMI, who were represented by the oldest
individuals with the most comorbidity. The proportion of unspeciﬁedTable 3
Association of Invasive Management With a Risk of Death (n ¼ 525)
HR (95% CI) P Value
Unadjusted 0.30 (0.19e0.47) <.001
Model 1* 0.35 (0.21e0.59) <.001
Model 2y 0.34 (0.20e0.58) <.001
*Model 1 is adjusted for type of AMI, gender, age, MMSE score, type of dementia
disorder, registration unit, history of AMI and a comorbidity score.
yModel 2 is adjusted for type of AMI, gender, age, MMSE score, type of dementia
disorder, registration unit, history of AMI and total number of drugs.
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patients hospitalized for AMI.30 This suggests diagnostic difﬁculties as
well as limited therapeutic efforts in this group of patients.
This study indicates that severity of cognitive impairment de-
termines the utilization of invasive procedures for management of
AMI in patients with dementia. Inadequate communication of symp-
toms, delays in arrival to the hospital, or initiation of diagnostic pro-
cedures may explain this ﬁnding. Particularly in patients with NSTEMI
and unspeciﬁed AMI, higher age was associated with lower odds of
being managed invasively, independently of cognitive status and co-
morbidity. This suggests that advanced age itself limits a possibility of
beingmanaged invasively, likely due to atypical presentation of AMI in
the oldest patients or personal judgements of physicians about pa-
tients’ frailty. As opposed to previous reports,8,9 this study does not
indicate that women have a lower chance of being offered optimal
treatment for AMI. In the present study, we found that women were
less frequently managed invasively than men; however, this could be
explained mainly by their age, cognitive status, and type of AMI.
Previous studies indicate that dementia is a barrier to receiving
invasive management for AMI, possibly because of uncertain beneﬁts
and insufﬁcient guidance to physicians.10e13 The oldest old patients
have been largely excluded from randomized clinical trials and most
observational studies assessing the treatment of AMI in elderly people
did not consider dementia/cognition in their analysis.1,3 One obser-
vational study showed that use of coronary angiography and PCI is
associated with lower in-hospital mortality in patients with demen-
tia.11 The present study, investigating postdischarge survival of pa-
tients with dementia, implies that they beneﬁt from the invasive
management of AMI and supports its use in this group of patients.
Future studies should conﬁrm this ﬁnding among patients at a more
severe stage of dementia and those who live in nursing homes.
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